TIM3 Antikörper
Kurzübersicht für TIM3 Antikörper (ABIN360940)
Target
Alle TIM3 (TIM 3) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Spezifität
- This antibody detects of TIM-3. It does not cross-react with Mouse TIM-1 and TIM-2.
-
Aufreinigung
- Protein A/G Affinity Chromatography
-
Immunogen
- Purified Mouse recombinant TIM-3
-
Isotyp
- IgG2
-
-
-
-
Applikationshinweise
-
Western Blot: 1/500 - 1/1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Rekonstitution
- Restore with 200 μL sterile PBS and the final concentration is 500 μg/mL.
-
Buffer
- PBS without preservatives or stabilizers
-
Konservierungsmittel
- Without preservative
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))
-
Andere Bezeichnung
- TIMD3 / HAVCR2
-
Substanzklasse
- Virus
-
Hintergrund
- TIM-3 has been identified as a Th1 specific marker initially due to expression on activated and polarized Th1 cells and absence on naive T cells. It has also been found on CD8+ T cells, Th17, Tregs , monocytes and dendritic cells. As a transmemebrane protein, TIM-3 is also referred to as 'T cell immunoglobulin and mucin-like domain containing protein -3.' Enhanced surface expression on CD4+ and CD8+ cells in the CNS are indicative of disease in EAE, murine models of MS. TIM-3 mediated down regulation of Th1 immune responses and induction of immune tolerance illustrate a potential key role for TIM-3 in immunoregulation.Synonyms: HAVCR-2, Hepatitis A virus cellular receptor 2, T-cell membrane protein 3, TIM-3, TIM3, TIMD-3
-
Gen-ID
- 171285
-
NCBI Accession
- NP_599011
-
UniProt
- Q8VIM0
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints
Target
-